Company Overview of XW Laboratories Inc.
XW Laboratories Inc., a biopharmaceutical company, focuses on developing a portfolio of internally discovered product candidates for the treatment of neurological disorders. The company focuses on developing a series of new CNS drugs that exhibit advantages leading to improved patients' compliance/convenience and/or lowered toxicity profile during drug treatment. Its platforms include Prodrug and Functional Group Switch that allow for quick paths to identify novel candidates by reducing the development cost/time to achieve clinical proof of concept. The company primarily focuses on the China market. It also serves foreign markets via collaboration with other companies. The company is based i...
Building C4 East
No. 666 Gaoxin Road
East Lake Hi-tech Development Zone
86 27 8763 6577
86 27 8763 5577
Key Executives for XW Laboratories Inc.
XW Laboratories Inc. does not have any Key Executives recorded.
XW Laboratories Inc. Key Developments
XW Laboratories Inc. Announces an Exclusive Licensing Agreement with the University of Pittsburgh to Develop Novel Mitochondria-Targeting Compounds
Mar 6 17
XW Laboratories Inc. announced an exclusive licensing agreement with the University of Pittsburgh to further commercialize a class of novel compounds based on pioneering mitochondria targeted bis-nitroxide technology developed in the laboratory of Professor Peter Wipf. Mitochondria control energetics, metabolic pathways, stress response and cell death, and are central to many human diseases. Over the past decade, the Wipf lab has played a major role in designing small molecule therapeutics that regulate mitochondrial processes and manage lipid membrane composition. The novel mitochondria targeted bis-nitroxide compounds licensed by XW Labs present a unique opportunity for the company to develop new therapies for a broad range of possible indications in the Central Nervous System (CNS) and oncology. Professor Wipf and his research group have developed mitochondrial targeted proof-of-concept compounds that have demonstrated efficacy in animal disease models such as Huntington's Disease and Traumatic Brain Injury. Their research findings have been published in high-profile journals including Nature Neuroscience and Cell Reports. In the two and half years since its foundation, XW Labs has established a diversified portfolio in the CNS area. The company's program, which is currently going through pre-clinical toxicology studies, features an internally developed novel prodrug compound for two CNS indications. Phase 1 clinical trials for this program are expected to be launched in the second half of 2017.
XW Laboratories Inc. Presents at ChinaBio Partnering Forum 2016, May-18-2016
May 15 16
XW Laboratories Inc. Presents at ChinaBio Partnering Forum 2016, May-18-2016 . Venue: Suzhou, China.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 20, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries